Study of METTL3 peptide inhibitors for urinary tumors
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new type of drug called METTL3 peptide inhibitors that may help your immune system fight urinary system tumors more effectively. The study aims to see how these inhibitors reshape the tumor environment to boost an anti-tumor immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a urinary system tumor (like bladder, kidney, or prostate cancer) through a biopsy or other test.
- You are at a specific stage of cancer and are being treated with surgery to remove the tumor.
- The tissue removed during surgery must meet certain standards for testing.
- You are willing to join the study and sign a consent form.
- You are between 18 and 75 years old.
- You do not have any serious mental health conditions or intellectual disabilities that would interfere with participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
This study uses urine “omics” tests (detailed lab patterns from urine) to predict whether immunotherapy will work for people with metastatic urothelial (bladder/urinary tract) cancer. It may help doctors choose the right treatment sooner by identifying who is more likely to benefit.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.